Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
Status:
Completed
Trial end date:
2018-11-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the percentage of participants with perianal fistula
healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram
(mg) in participants with fistulizing Crohn's disease (CD).